DYN – dyne therapeutics, inc. (US:NASDAQ)

News

Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Raymond James to a "strong-buy" rating.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $46.00 price target on the stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com